| SKŘIČKOVÁ, Jana, Renata CHLOUPKOVÁ, Zbyněk BORTLÍČEK, M. PESEK, V. KOLEK, Karel HEJDUK, L. KOUBKOVA, M. ČERNOVSKA, J. KREJCI, M. ZEMANOVA, L. HAVEL, J. ROUBEC, M. HRNCIARIK, F. SALAJKA, H. COUPKOVA, Monika ŠATÁNKOVÁ, Andrea BENEJOVÁ, I. GRYGARKOVA a P. OPALKA. Characteristics of NSCLC Patients Treated in First Line Treatment with Tyrosine Kinase Inhibitors (TKI) - Real Data from the Czech Republic. 2017. |
Další formáty:
BibTeX
LaTeX
RIS
@proceedings{1395573,
author = {Skřičková, Jana and Chloupková, Renata and Bortlíček, Zbyněk and Pesek, M. and Kolek, V. and Hejduk, Karel and Koubkova, L. and černovska, M. and Krejci, J. and Zemanova, M. and Havel, L. and Roubec, J. and Hrnciarik, M. and Salajka, F. and Coupkova, H. and Šatánková, Monika and Benejová, Andrea and Grygarkova, I. and Opalka, P.},
keywords = {Tyrosine Kinase Inhibitors},
language = {eng},
title = {Characteristics of NSCLC Patients Treated in First Line Treatment with Tyrosine Kinase Inhibitors (TKI) - Real Data from the Czech Republic},
year = {2017}
}
TY - CONF
ID - 1395573
AU - Skřičková, Jana - Chloupková, Renata - Bortlíček, Zbyněk - Pesek, M. - Kolek, V. - Hejduk, Karel - Koubkova, L. - černovska, M. - Krejci, J. - Zemanova, M. - Havel, L. - Roubec, J. - Hrnciarik, M. - Salajka, F. - Coupkova, H. - Šatánková, Monika - Benejová, Andrea - Grygarkova, I. - Opalka, P.
PY - 2017
TI - Characteristics of NSCLC Patients Treated in First Line Treatment with Tyrosine Kinase Inhibitors (TKI) - Real Data from the Czech Republic
KW - Tyrosine Kinase Inhibitors
N2 - Characteristics of NSCLC Patients Treated in First Line Treatment with Tyrosine Kinase Inhibitors (TKI) - Real Data from the Czech Republic.
ER -
SKŘIČKOVÁ, Jana, Renata CHLOUPKOVÁ, Zbyněk BORTLÍČEK, M. PESEK, V. KOLEK, Karel HEJDUK, L. KOUBKOVA, M. ČERNOVSKA, J. KREJCI, M. ZEMANOVA, L. HAVEL, J. ROUBEC, M. HRNCIARIK, F. SALAJKA, H. COUPKOVA, Monika ŠATÁNKOVÁ, Andrea BENEJOVÁ, I. GRYGARKOVA a P. OPALKA. \textit{Characteristics of NSCLC Patients Treated in First Line Treatment with Tyrosine Kinase Inhibitors (TKI) - Real Data from the Czech Republic}. 2017.
|
